The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Six Monthly Return

14 Sep 2020 16:30

RNS Number : 9441Y
4d Pharma PLC
14 September 2020
 

14 September 2020

 

4D pharma plc

 

(the "Company" or "4D")

 

Block Listing Six Monthly Return

 

Name of applicant:

4D Pharma plc

Name of scheme:

Block Admission for February 2020 warrants

Period of return:

From:

10 March 2020

To:

9 September 2020

Number of securities originally admitted at date of admission:

22,000,000 Ordinary Shares of 0.25p each on 10 March 2020

Balance of unallotted securities under scheme(s) from previous return:

22,000,000 Ordinary shares

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0 Ordinary shares

Less: Number of securities issued/allotted under scheme(s) during period:

0 Ordinary shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

22,000,000 Ordinary shares

 

Name of contact:

Duncan Peyton

Telephone number of contact:

Company Secretary (0113 895 0130)

 

 

Contact Information:

4D

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBUGDCIBBDGGS
Date   Source Headline
23rd Sep 20147:00 amRNSInterim results for the period ended 30 June 2014
10th Sep 201410:49 amRNSHolding(s) in Company
10th Sep 201410:45 amRNSHolding(s) in Company
2nd Sep 20147:00 amRNSResearch Update
7th Aug 20147:00 amRNSRosburix granted orphan drug designation
18th Jul 20147:00 amRNSAcquisition of The Microbiota Company Limited
15th Jul 20145:52 pmRNSHolding(s) in Company
15th Jul 20145:38 pmRNSHolding(s) in Company
11th Jul 201412:37 pmRNSResult of general meeting
10th Jul 20143:43 pmRNSHolding(s) in Company
25th Jun 20147:00 amRNSPlacing
4th Jun 20147:00 amRNSAcquisition
4th Mar 20147:04 amRNSIssue of Convertible Loan
20th Feb 20147:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.